Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aprea Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Aprea Therapeutics, Inc.

APRE

Aprea Therapeutics, Inc.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology through synthetic lethality. It develops small molecule inhibitors targeting DNA damage response (DDR) pathways, including WEE1 and ATR kinases, to selectively kill cancer cells with specific genetic mutations while minimizing toxicity. Aprea’s pipeline focuses on advanced solid tumors, leveraging integrated discovery platforms to identify novel targets and biomarkers, retaining global rights for development and commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aprea Therapeutics, Inc.

1
1
Aprea Therapeutics, Inc. Aprea Therapeutics Reports $3.3 Million Net Loss and Strengthens Financial Position with $46.5 Million Cash

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Aprea Therapeutics, Inc. Aprea Therapeutics Reports 99% Revenue Decline and $2.97 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Aprea Therapeutics, Inc. Aprea Therapeutics Reports $3.2 Million Net Loss in Q2 2025, Seeks Additional Funding

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Aprea Therapeutics, Inc. Aprea Therapeutics Reports $3.9 Million Net Loss in Q1 2025, Seeks Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Aprea Therapeutics, Inc. Aprea Therapeutics Reports $12.96 Million Net Loss for 2024, Grant Revenue Increases

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aprea Therapeutics, Inc. Aprea Therapeutics Reports Improved Financials, Increased Cash Position, and Progress in Clinical Programs

Via official filing (AI summary) | over 1 year ago | 0 comments